{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"3","upperLimit":"8","value":"5.5"},{"groupId":"OG001","lowerLimit":"1","upperLimit":"9","value":"4"},{"groupId":"OG002","lowerLimit":"1","upperLimit":"8","value":"3.5"},{"groupId":"OG003","lowerLimit":"1","upperLimit":"12","value":"2"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"2"},{"groupId":"OG001","value":"3"},{"groupId":"OG002","value":"6"},{"groupId":"OG003","value":"13"},{"groupId":"OG004","value":"0"}],"units":"Participants"}],"description":"Progression-free survival is the time from start of treatment to disease progression or death from any cause. Disease progression was assessed by the Response Evaluation Criteria in Solid Tumors (RECIST) v1.1. Disease progression is at least a 20% increase in the sum of the diameters of target lesions, taking as reference the smallest sum on study. The appearance of one or more new lesions is also considered progressions.","dispersionType":"Full Range","groups":[{"description":"Phase I: Dose Escalation Cohort; Arm 1: Phase I; Dose Level (DL) 1: 1 x 10\\^9 E7 T-Cell Receptor (TCR) Cells. Arm 1, Phase I, Non-myeloablative, lymphocyte depleting preparative regimen, followed by E7 TCR cells at escalating doses, followed by Aldesleukin.","id":"OG000","title":"Phase I:Dose Escalation Cohort; Arm 1:Phase I:DoseLevel 1: 1 x 10^9 E7 T-Cell Receptor (TCR) Cells"},{"description":"Phase I: Dose Escalation Cohort; Arm 1: Phase I; Dose Level (DL) 2: 1 x 10\\^10 E7 T-Cell Receptor (TCR) Cells. Arm 1, Phase I, Non-myeloablative, lymphocyte depleting preparative regimen, followed by E7 TCR cells at escalating doses, followed by Aldesleukin.","id":"OG001","title":"Phase I: Dose Escalation Cohort; Arm 1: Phase I; Dose Level 2: 1 x 10^10 E7 T-Cell Receptor Cells"},{"description":"Phase I: Dose Escalation Cohort; Arm 1: Phase I; Dose Level (DL) 3: 1 x 10\\^11 E7 Cells. Arm 1, Phase I, Non-myeloablative, lymphocyte depleting preparative regimen, followed by E7 T-Cell Receptor (TCR) Cells at escalating doses, followed by Aldesleukin.","id":"OG002","title":"Phase I: Dose Escalation Cohort; Arm 1: Phase I; Dose Level 3: 1 x 10^11 E7 Cells"},{"description":"Phase II Cohort; Arm 2: Phase II; 1 x 10\\^11 E7 Cells that were determined in Phase I + Aldesleukin.","id":"OG003","title":"Phase II Cohort; Arm 2: Phase II: 1 x 10^11 E7 Cells"},{"description":"Participants were enrolled but were not treated and not assigned to Arm/Cohorts.","id":"OG004","title":"Participants Enrolled But Were Not Treated"}],"paramType":"MEDIAN","populationDescription":"24/224 participants were analyzed because 200 were not evaluable for this outcome.","reportingStatus":"POSTED","timeFrame":"From the time of cell infusion (Day 0) until documented progressive disease; a maximum of 12 months","title":"Progression-free Survival","type":"SECONDARY","unitOfMeasure":"Months"}